PMID- 22965266
OWN - NLM
STAT- MEDLINE
DCOM- 20130214
LR  - 20151119
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 19
IP  - 10
DP  - 2012 Oct
TI  - Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to 
      local clinical subtyping in breast cancer patients.
PG  - 3257-63
LID - 10.1245/s10434-012-2561-6 [doi]
AB  - PURPOSE: To compare breast cancer subtyping with the three centrally assessed 
      microarray-based assays BluePrint, MammaPrint, and TargetPrint with locally 
      assessed clinical subtyping using immunohistochemistry (IHC) and fluorescence in 
      situ hybridization (FISH). METHODS: BluePrint, MammaPrint, and TargetPrint were 
      all performed on fresh tumor samples. Microarray analysis was performed at 
      Agendia Laboratories, blinded for clinical and pathological data. IHC/FISH 
      assessments were performed according to local practice at each institution; 
      estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
      factor receptor 2 (HER2) assessments were performed on 132 samples, and Ki-67 on 
      79 samples. RESULTS: The concordance between BluePrint and IHC/FISH subtyping was 
      94 % for the Luminal-type, 95 % for the HER2-type, and 94 % for the Basal-type 
      subgroups. The concordance of BluePrint with subtyping using mRNA single gene 
      readout (TargetPrint) was 96 % for the Luminal-type, 97 % for the HER2-type, and 
      98 % for the Basal-type subgroups. The concordance for substratification into 
      Luminal A and B using MammaPrint and Ki-67 was 68 %. The concordance between 
      TargetPrint and IHC/FISH was 97 % for ER, 80 % for PR, and 95 % for HER2. 
      CONCLUSIONS: The implementation of multigene assays such as TargetPrint, 
      BluePrint, and MammaPrint may improve the clinical management of breast cancer 
      patients. High discordance between Luminal A and B substratification based on 
      MammaPrint versus locally assessed Ki-67 or grade indicates that chemotherapy 
      decisions should not be based on the basis of Ki-67 readout or tumor grade alone. 
      TargetPrint serves as a second opinion for those local pathology settings where 
      high-quality standardization is harder to maintain.
FAU - Nguyen, Bichlien
AU  - Nguyen B
AD  - Department of Medicine, Todd Cancer Institute, Long Beach Memorial Medical 
      Center, Long Beach, CA, USA. bnguyen1@memorialcare.org
FAU - Cusumano, Pino G
AU  - Cusumano PG
FAU - Deck, Kenneth
AU  - Deck K
FAU - Kerlin, Deborah
AU  - Kerlin D
FAU - Garcia, Agustin A
AU  - Garcia AA
FAU - Barone, Julie L
AU  - Barone JL
FAU - Rivera, Edgardo
AU  - Rivera E
FAU - Yao, Katharine
AU  - Yao K
FAU - de Snoo, Femke A
AU  - de Snoo FA
FAU - van den Akker, Jeroen
AU  - van den Akker J
FAU - Stork-Sloots, Lisette
AU  - Stork-Sloots L
FAU - Generali, Daniele
AU  - Generali D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120815
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics/*metabolism
MH  - Breast Neoplasms/*classification/genetics/metabolism/pathology
MH  - Female
MH  - *Gene Expression Profiling
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Ki-67 Antigen/metabolism
MH  - Microarray Analysis
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
MH  - RNA, Messenger/*genetics
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Survival Rate
EDAT- 2012/09/12 06:00
MHDA- 2013/02/15 06:00
CRDT- 2012/09/12 06:00
PHST- 2012/04/17 00:00 [received]
PHST- 2012/09/12 06:00 [entrez]
PHST- 2012/09/12 06:00 [pubmed]
PHST- 2013/02/15 06:00 [medline]
AID - 10.1245/s10434-012-2561-6 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 
      2012 Aug 15.